% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Dietlein:874917,
      author       = {Dietlein, Felix and Hohberg, Melanie and Kobe, Carsten and
                      Zlatopolskiy, Boris D. and Krapf, Philipp and Endepols,
                      Heike and Täger, Philipp and Hammes, Jochen and
                      Heidenreich, Axel and Neumaier, Bernd and Drzezga, Alexander
                      and Dietlein, Markus},
      title        = {{A}n 18 {F}-{L}abeled {PSMA} {L}igand for {PET}/{CT} of
                      {P}rostate {C}ancer: {F}irst-in-{H}umans {O}bservational
                      {S}tudy and {C}linical {E}xperience with 18
                      {F}-{JK}-{PSMA}-7 {D}uring the {F}irst {Y}ear of
                      {A}pplication},
      journal      = {Journal of nuclear medicine},
      volume       = {61},
      number       = {2},
      issn         = {2159-662X},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {FZJ-2020-01701},
      pages        = {202 - 209},
      year         = {2020},
      abstract     = {In preclinical trials, the recently developed tracer
                      2-methoxy-18F-DCFPyL (18F-JK-prostate-specific membrane
                      antigen [PSMA]-7) has shown favorable properties regarding
                      clinical performance and radiochemical accessibility. The
                      aim of this study was to evaluate the clinical utility of
                      18F-JK-PSMA-7 for PET/CT imaging of patients with prostate
                      cancer. Methods: In an Institutional Review Board–approved
                      pilot study, the initial clinical utility of PET/CT imaging
                      with 18F-JK-PSMA-7 was directly compared with 68Ga-PSMA-11
                      PET/CT in a group of 10 patients with prostate cancer. The 2
                      PSMA tracers were administered to each patient less than 3
                      wk apart. Next, we analyzed the data of 75 consecutive
                      patients who had undergone clinical 18F-JK-PSMA-7 PET/CT
                      imaging for tumor localization of biochemical recurrence
                      (BCR). Results: The pilot study in 10 patients who were
                      examined with both PSMA tracers demonstrated that
                      18F-JK-PSMA-7 was at least equivalent to 68Ga-PSMA-11. All
                      unequivocally 68Ga-PSMA-11–positive lesions could be also
                      detected using 18F-JK-PSMA-7, and in 4 patients additional
                      suspected PSMA-positive lesions were identified (1 patient
                      changed from PSMA-negative to PSMA-positive). In patients
                      with BCR (after prostatectomy or radiotherapy), the capacity
                      of 18F-JK-PSMA-7 PET/CT to detect at least one PSMA-positive
                      lesion was $84.8\%.$ The prostate-specific antigen
                      (PSA)–stratified detection rate of 18F-JK-PSMA-7 after
                      prostatectomy varied among $54.5\%$ (6/11 patients; PSA <
                      0.5 μg/L), $87.5\%$ (14/16 patients; PSA 0.5–2 μg/L),
                      and $90.9\%$ (20/22 patients; PSA > 2 μg/L). Conclusion:
                      The tracer 18F-JK-PSMA-7 was found to be safe and clinically
                      useful. We demonstrated that 18F-JK-PSMA-7 was not inferior
                      when directly compared with 68Ga-PSMA-11 in a pilot study
                      but indeed identified additional PSMA-avid suspected lesions
                      in oligometastasized patients with BCR. In a subsequent
                      analysis of a clinical cohort of BCR patients, 18F-JK-PSMA-7
                      was useful in tumor localization. 18F-JK-PSMA-7 is
                      recommended for future prospective trials.},
      cin          = {INM-5 / INM-2},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-5-20090406 / I:(DE-Juel1)INM-2-20090406},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31324713},
      UT           = {WOS:000512119600013},
      doi          = {10.2967/jnumed.119.229542},
      url          = {https://juser.fz-juelich.de/record/874917},
}